NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 247 filers reported holding NEKTAR THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $0 | – | 9 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | – | 9 | 0.0% | 0.00% | – |
| Q1 2022 | $0 | – | 9 | +12.5% | 0.00% | – |
| Q4 2021 | $0 | – | 8 | +700.0% | 0.00% | – |
| Q4 2020 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q3 2020 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q2 2020 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | – | 1 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | -100.0% | 1 | -100.0% | 0.00% | -100.0% |
| Q3 2019 | $2,348,000 | -73.2% | 128,906 | -47.7% | 0.01% | +66.7% |
| Q2 2019 | $8,770,000 | +116.1% | 246,538 | +104.1% | 0.00% | -50.0% |
| Q1 2019 | $4,058,000 | +19.6% | 120,803 | +17.0% | 0.01% | 0.0% |
| Q4 2018 | $3,394,000 | -50.3% | 103,271 | -7.8% | 0.01% | -50.0% |
| Q3 2018 | $6,825,000 | +35.0% | 111,980 | +8.1% | 0.01% | +20.0% |
| Q2 2018 | $5,056,000 | -37.2% | 103,553 | +36.7% | 0.01% | -44.4% |
| Q1 2018 | $8,048,000 | – | 75,759 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |